Hologic, Inc.
250 Campus Drive
Marlborough
Massachusetts
01752
United States
Tel: 781-999-7300
Fax: 781-280-0669
Website: http://www.hologic.com/
Email: support@hologic.com
642 articles about Hologic, Inc.
-
Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences - May 05, 2021
5/5/2021
Hologic, Inc. announced that the Company will present at these upcoming virtual investor conferences
-
Hologic Announces Financial Results for Second Quarter of Fiscal 2021
4/28/2021
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 27, 2021.
-
Hologic to Acquire Mobidiag, Innovator in Near-Patient, Acute Care Diagnostic Testing, for Approximately $795 Million
4/8/2021
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has signed a definitive agreement to acquire Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, for an enterprise value of approximately $795 million.
-
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2021 on Wednesday, April 28, 2021
4/7/2021
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2021 on Wednesday, April 28, after the market closes.
-
Hologic Receives Gallup Exceptional Workplace Award
3/22/2021
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has been named a winner of the 2021 Gallup Exceptional Workplace Award, the Company announced today.
-
Hologic Acquires European Molecular Diagnostic Company Diagenode for Approximately $159 Million
3/1/2021
-- Transaction Expands and Diversifies Hologic’s Diagnostic Business Across Test Menu, Customer Segments and Geography –
-
Hologic Completes Acquisition of Biotheranostics, Enabling Entry into Growing Oncology Market
2/22/2021
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has completed its previously announced acquisition of molecular oncology leader Biotheranostics, Inc. for approximately $230 million.
-
New Research Published in the Journal of the American College of Radiology Confirms Black Women More Likely to Receive Inferior Breast Cancer Screening Than White Women, Points to Need for Stronger Breast Health Equity Reform
2/19/2021
Review of more than 800,000 mammograms reveals Black women less likely to be screened via digital breast tomosynthesis, despite the technology being proven superior to traditional mammography for all women
-
Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences
2/10/2021
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at these upcoming virtual investor conferences:
-
Hologic’s New Sustainability Report Highlights How the Company’s Purpose-Driven Culture is Making a Unique Difference in the World
2/4/2021
Hologic, Inc. (Nasdaq: HOLX) announced today the on-line publication of its 2020 sustainability report, “The Power of Purpose.”
-
Hologic and Google Cloud Announce Collaboration to Advance Next Generation Digital Diagnostic Capabilities
2/1/2021
Hologic, Inc. (Nasdaq: HOLX) announced today a multi-year strategic collaboration with Google Cloud that will feature the integration of Google Cloud’s machine learning (ML) technologies with Hologic’s cutting-edge Genius™ Digital Diagnostics System to transform screening and accelerate the eradication of cervical cancer across the globe.
-
Hologic Announces Financial Results for First Quarter of Fiscal 2021
1/27/2021
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 26, 2020.
-
Hologic Announces Preliminary Financial Results for First Quarter of Fiscal 2021
1/8/2021
Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 26, 2020.
-
Hologic to Announce Financial Results for the First Quarter of Fiscal 2021 on Wednesday, January 27, 2021
1/8/2021
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2021 on Wednesday, January 27, after the market closes.
-
Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers, for Approximately $230 Million
1/5/2021
– Transaction Accelerates Hologic’s Entry into Oncology Growth Market, Provides New Lab Capabilities – – Hologic’s Commercial Resources, Expertise in Molecular Automation Expected to Boost Biotheranostics Growth –
-
Hologic to Acquire SOMATEX, Leader in Biopsy Site Markers and Localization Technologies, for $64 Million
1/4/2021
Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, announced today it has completed the acquisition of SOMATEX Medical Technologies GmbH, a leader in biopsy site markers and localization technologies, for approximately $64 million.
-
Hologic to Webcast Presentation at the 39th Annual J.P. Morgan Healthcare Conference
12/28/2020
Hologic to Webcast Presentation at the 39 th Annual J.P. Morgan Healthcare Conference
-
Hologic Receives FDA Clearance for Latest Breakthrough in Early Breast Cancer Detection, Genius AI™ Detection
12/1/2020
Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, today announced U.S. Food and Drug Administration (FDA) clearance and commercial availability of the Company’s Genius AI™ Detection technology, a new deep learning-based software designed to help radiologists detect subtle potential cancers in breast tomosynthesis images.
-
Hologic to Showcase Products Across Breast Cancer Screening, Biopsy, Surgery and Treatment at Virtual RSNA 2020
11/27/2020
Hologic, Inc. (Nasdaq: HOLX) will virtually showcase its extensive portfolio of breast and skeletal health products, including screening, surgical, interventional, ultrasound and skeletal solutions, at the 106 th Scientific Assembly and Annual Meeting of the Radiological S
-
Hologic to Webcast Presentation at Upcoming Virtual Investor Conference
11/25/2020
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present virtually at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2 at 4:20 p.m. Eastern Time.